Back to top
more

Enovis (ENOV)

(Delayed Data from NYSE)

$26.46 USD

26.46
974,186

-0.17 (-0.64%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $26.42 -0.04 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 9.46% and 0.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Options Traders Betting on a Big Move in Enovis (ENOV) Stock?

by Zacks Equity Research

Investors need to pay close attention to Enovis (ENOV) stock based on the movements in the options market lately.

Zacks Equity Research

Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 6.52% and 0.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Talkspace, Inc. (TALK) Q4 Earnings Meet Estimates

by Zacks Equity Research

Talkspace (TALK) delivered earnings and revenue surprises of 0% and 3.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks Industry Outlook Enovis, Omnicell and Phreesia

by Zacks Equity Research

Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave.

Zacks Equity Research

Centene Expands Care in Hawaii With a Residential Program

by Zacks Equity Research

CNC's 'Ohana Health Plan joins forces with Hope Services Hawaii to launch a residential program offering integrated clinical care for members facing homelessness and complex health needs.

Zacks Equity Research

Company News for Jan 10, 2025

by Zacks Equity Research

Companies In The News Are: EIX, CEG, EBAY, META, CART, ENOV.

Zacks Equity Research

Here's Why Investors Should Retain Molina Healthcare Stock for Now

by Zacks Equity Research

MOH remains well-poised for growth, attributable to improved premium revenues, buyouts and an aging U.S. population.

Zacks Equity Research

Enovis (ENOV) Upgraded to Buy: Here's Why

by Zacks Equity Research

Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 38.95% Upside in Enovis (ENOV): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 15.87% and 0.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene

by Zacks Equity Research

Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.

Zacks Equity Research

Enovis (ENOV) Q2 Earnings Top Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 3.33% and 0.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Standard BioTools (LAB) delivered earnings and revenue surprises of -33.33% and 22.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?

by Debanjana Dey

Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.

Zacks Equity Research

Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares

by Zacks Equity Research

Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.

Zacks Equity Research

Zacks.com featured highlights include Energizer, Super League Enterprise and Enovis

by Zacks Equity Research

Energizer, Super League Enterprise and Enovis have been highlighted in this Screen of The Week article.

Zacks Equity Research

Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis

by Zacks Equity Research

Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.

Sanghamitra Saha headshot

Bet on 3 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Energizer (ENR), Super League Enterprise Inc. (SLE) and Enovis (ENOV).

Zacks Equity Research

What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?

by Zacks Equity Research

Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.

Zacks Equity Research

Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release

by Zacks Equity Research

Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.

Nalak Das headshot

5 Medical Info Systems Stock to Buy for a Stable Portfolio

by Nalak Das

We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.